Delisting riskPopularity #4,473
Xenetic Biosciences (XBIO)
Develops DNase-based adjuncts for cancer therapy and armored CAR-T treatment.
$2.64
After-hours close+0.07 (+2.72%)
At close$2.57(−14.05%)
Something off on this page? Send us feedback.
Next report
Nov 6, 26
in 45 days
EPS estimate
—
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.68−$0.59−$0.45−$0.33−$0.22−$0.20−$0.41Pending
Estimate−$0.68−$0.72−$0.64−$0.49−$0.52———
Surprise0.0%+18.1%+29.7%+32.7%+57.7%———
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$650.0K$590.0K$589.9K$1.0M$766.3K$806.9K$660.6KPending
Estimate$650.0K$670.0K$479.0K$630.0K$690.0K———
Surprise0.0%−11.9%+23.2%+63.0%+11.1%———
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | — | — | — |
| Aug 2026 | — | −$0.41 | — |
| May 2026 | — | −$0.20 | — |
| Mar 2026 | −$0.52 | −$0.22 | +57.7% |
| Nov 2025 | −$0.49 | −$0.33 | +32.7% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Apr 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | — | — | — | — | — | — | — |
| Aug 6, 2026 | — | −$0.41 | — | — | $660.6K | — | −3.7% |
| May 12, 2026 | — | −$0.20 | — | — | $806.9K | — | +5.3% |
| Mar 12, 2026 | −$0.52 | −$0.22 | +57.7% | $690.0K | $766.3K | +11.1% | +9.3% |
| Nov 12, 2025 | −$0.49 | −$0.33 | +32.7% | $630.0K | $1.0M | +63.0% | −3.3% |
| Aug 12, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 18, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 10, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 23, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 12, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 22, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 12, 2020 | |||||||
| Aug 12, 2020 | |||||||
| May 14, 2020 | |||||||
| Mar 26, 2020 | |||||||
| Nov 15, 2019 | |||||||
| Aug 15, 2019 | |||||||
| May 10, 2019 | |||||||
| Mar 29, 2019 | |||||||
| Nov 9, 2018 | |||||||
| Aug 10, 2018 | |||||||
| May 15, 2018 | |||||||
| Mar 30, 2018 | |||||||
| Nov 15, 2017 | |||||||
| Aug 14, 2017 | |||||||
| May 16, 2017 | |||||||
| Apr 3, 2017 | |||||||
| Nov 15, 2016 | |||||||
| Aug 15, 2016 | |||||||
| May 16, 2016 | |||||||
| Mar 30, 2016 | |||||||
| Nov 16, 2015 | |||||||
| Aug 19, 2015 |